RIDE and RISE were parallel, 24-month, multinational, double-masked, sham-injection controlled, randomized phase 3 studies designed to evaluate the efficacy of ranibizumab in patients with DME. The studies enrolled 759 patients (RISE enrolled 377 patients; RIDE enrolled 382 patients) with confirmed vision loss as a result of DME. All enrolled patients had a BCVA between 20/40 and 30/320, and all enrolled patients had central subfield thickness of at least 275 microns (as confirmed on OCT).

Quiz Module 10.7

1. RIDE and RISE were designed to study efficacy and safety of:

2. Ranibizumab was the second anti-VEGF agent approved for DME, the first agent approved was: